Pediatric Nephrology

, Volume 21, Issue 3, pp 344–349 | Cite as

Differential risk of remission and ESRD in childhood FSGS

  • Debbie S. Gipson
  • Hyunsook Chin
  • Trevor P. Presler
  • Caroline Jennette
  • Maria E. Ferris
  • Susan Massengill
  • Keisha Gibson
  • David B. Thomas
Original Article

Abstract

Focal segmental glomerulosclerosis (FSGS) is the leading cause of steroid-resistant nephrotic syndrome in childhood and the most common form of end stage renal disease (ESRD) from glomerular disease. In order to assess the risk of progression of children with primary FSGS and the impact of proteinuria remission status on disease progression, we undertook this study to describe a cohort of 60 children and adolescents from the Glomerular Disease Collaborative Network. Of the 60 patients included in the cohort, 58% were African American. Median age was 16 years. Proteinuria ranged from 1.0–24.0 g/day/1.73 m2; 57% were hypertensive, and the median estimated glomerular filtration rate (eGFR) was 90.2 ml/min/1.73 m2. Complete remission was achieved in 20%, partial remission in 33%, and 47% have not achieved remission during follow-up with all prescribed therapy. Only ACE-I/ARB therapy was predictive of proteinuria remission in multivariate analysis (hazard ratio [HR] 3.35; 95% confidence interval [CI] 1.42–7.92). Renal survival was much improved in patients with complete or partial remission compared with no remission in univariate analysis. In multivariate analysis comparing no remission status, complete remission was associated with a 90% decreased risk of ESRD (HR 0.10, 95% CI 0.01–0.79, p =0.03). In summary, proteinuria remission status is a valid predictor of long-term renal survival in children with FSGS.

Keywords

ESRD Focal segmental glomerulosclerosis Glomerular Disease Collaborative Network Proteinuria 

References

  1. 1.
    Mitsnefes M, Stablein D (2005) Hypertension in pediatric patients on long-term dialysis: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Am J Kidney Dis 45:309–315PubMedGoogle Scholar
  2. 2.
    Eddy AA, Symons JM (2003) Nephrotic syndrome in childhood. Lancet 362:629–639CrossRefPubMedGoogle Scholar
  3. 3.
    (1981) The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 98:561–564Google Scholar
  4. 4.
    Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC (2005) Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 16:1061–1068CrossRefPubMedGoogle Scholar
  5. 5.
    Cattran D (2005) Management of membranous nephropathy: when and what for treatment. J Am Soc Nephrol 15:1188–1194CrossRefGoogle Scholar
  6. 6.
    Cameron JS, Turner DR, Ogg CS, Chantler C, Williams DG (1978) The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol 10:213–218PubMedGoogle Scholar
  7. 7.
    Velosa JA, Holley KE, Torres VE, Offord KP (1983) Significance of proteinuria on the outcome of renal function in patients with focal segmental glomerulosclerosis. Mayo Clin Proc 58:568–577PubMedGoogle Scholar
  8. 8.
    Beaufils H, Alphonse JC, Guedon J, Legrain M (1978) Focal glomerulosclerosis: natural history and treatment. A report of 70 cases. Nephron 21:75–85PubMedGoogle Scholar
  9. 9.
    Cattran DC, Rao P (1998) Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 32:72–79PubMedGoogle Scholar
  10. 10.
    Alexopoulos E, Stangou M, Papagianni A, Pantzaki A, Papadimitriou M (2000) Factors influencing the course and the response to treatment in primary focal segmental glomerulosclerosis. Nephrol Dial Transplant 15:1348–1356CrossRefPubMedGoogle Scholar
  11. 11.
    D’Agati VD, Fogo AB, Bruijn JA, Jennette JC (2004) Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 43:368–382CrossRefPubMedGoogle Scholar
  12. 12.
    Schwartz GJ, Haycock GB, Edelmann CM, Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259–263PubMedGoogle Scholar
  13. 13.
    Schwartz GJ, Gauthier B (1985) A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr 106:522–526PubMedGoogle Scholar
  14. 14.
    Schwartz GJ, Feld LG, Langford DJ (1984) A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr 104:849–854PubMedGoogle Scholar
  15. 15.
    Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedGoogle Scholar
  16. 16.
    Morales JV, Weber R, Wagner MB, Barros EJ (2004) Is morning urinary protein/creatinine ratio a reliable estimator of 24-hour proteinuria in patients with glomerulonephritis and different levels of renal function? J Nephrol 17:666–672PubMedGoogle Scholar
  17. 17.
    Watanabe M, Funabiki K, Tsuge T, Maeda K, Horikoshi S, Tomino Y (2005) Using protein/creatinine ratios in random urine. J Clin Lab Anal 19:160–166CrossRefPubMedGoogle Scholar
  18. 18.
    Allison PD (1995) Competing risks. 6, Survival Analysis using the SAS system: a practical guide. SAS Publishing, Cary, NC, USA, pp 185–209Google Scholar
  19. 19.
    Collett D (2003) Modelling survival data. Modelling survival data in medical research, 2nd edn. Chapman & Hall, London, pp 55–193Google Scholar
  20. 20.
    Kalbfleisch JD, Prentice RL (2002) The statistical analysis of failure time data, 2nd edn. Wiley, New York, p 462Google Scholar
  21. 21.
    Chun MJ, Korbet SM, Schwartz MM, Lewis EJ (2004) Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 15:2169–2177CrossRefPubMedGoogle Scholar
  22. 22.
    Bagga A, Mudigoudar BD, Hari P, Vasudev V (2004) Enalapril dosage in steroid-resistant nephrotic syndrome. Pediatr Nephrol 19:45–50CrossRefPubMedGoogle Scholar
  23. 23.
    Ruggenenti P, Perna A, Remuzzi G (2001) ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol 12:2832–2837PubMedGoogle Scholar
  24. 24.
    Chiurchiu C, Remuzzi G, Ruggenenti P (2005) Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses. J Am Soc Nephrol 16 [Suppl 1]:S58–S63Google Scholar
  25. 25.
    Heering P, Braun N, Mullejans R, Ivens K, Zauner I, Funfstuck R, Keller F, Kramer BK, Schollmeyer P, Risler T, Grabensee B (2004) Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am J Kidney Dis 43:10–18PubMedGoogle Scholar
  26. 26.
    Cattran D, Neogi T, Sharma R, McCarthy ET, Savin VJ (2003) Serial estimates of serum permeability activity and clinical correlates in patients with native kidney focal segmental glomerulosclerosis. J Am Soc Nephrol 14:448–453CrossRefPubMedGoogle Scholar
  27. 27.
    Lieberman KV, Tejani A (1996) A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 7:56–63PubMedGoogle Scholar
  28. 28.
    Ruf RG, Lichtenberger A, Karle SM, Haas JP, Anacleto FE, Schultheiss M, Zalewski I, Imm A, Ruf EM, Mucha B, Bagga A, Neuhaus T, Fuchshuber A, Bakkaloglu A, Hildebrandt F (2004) Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 15:722–732CrossRefPubMedGoogle Scholar
  29. 29.
    Orloff MS, Iyengar SK, Winkler CA, Goddard KA, Dart RA, Ahuja TS, Mokrzycki M, Briggs WA, Korbet SM, Kimmel PL, Simon EE, Trachtman H, Vlahov D, Michel DM, Berns JS, Smith MC, Schelling JR, Sedor JR, Kopp JB (2005) Variants in the Wilms’ tumor gene are associated with focal segmental glomerulosclerosis in the African American population. Physiol Genomics 21:212–221PubMedGoogle Scholar
  30. 30.
    Pollak MR (2002) Inherited podocytopathies: FSGS and nephrotic syndrome from a genetic viewpoint. J Am Soc Nephrol 13:3016–3023PubMedGoogle Scholar

Copyright information

© IPNA 2006

Authors and Affiliations

  • Debbie S. Gipson
    • 1
  • Hyunsook Chin
    • 1
  • Trevor P. Presler
    • 1
  • Caroline Jennette
    • 1
  • Maria E. Ferris
    • 1
  • Susan Massengill
    • 2
  • Keisha Gibson
    • 1
  • David B. Thomas
    • 3
  1. 1.UNC Kidney CenterUniversity of North CarolinaChapel HillUSA
  2. 2.Department of PediatricsCarolinas Medical CenterChapel HillUSA
  3. 3.Department of PathologyUniversity of North Carolina at Chapel HillChapel HillUSA

Personalised recommendations